Drug lookup | Fillwise

CHLORDIAZEPOXIDE

3 general benefit · 3 not a benefit

Other products in the same Health Canada class (N05BA) — coverage varies; not interchangeable

Alprazolam (Xanax): general benefit, Not a benefit
Bromazepam (Lectopam): general benefit, Not a benefit
Clorazepate dipotassium (Tranxene): general benefit, Not a benefit
Diazepam (Diazepam Injection USP): general benefit, Limited Use 481, Not a benefit
Lorazepam (Apo-Lorazepam): general benefit, Not a benefit
Oxazepam (Apo-Oxazepam): general benefit, Not a benefit

1 more in the class list below

Chlordiazepoxide · DIN 00522996 · 25mg · capsule

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Chlordiazepoxide · DIN 00522996 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2013-05-16 · brand CHLORDIAZEPOXIDE · ATC N05BA02 CHLORDIAZEPOXIDE · form Capsule · route Oral · ingredients CHLORDIAZEPOXIDE HYDROCHLORIDE 25 MG · company Aa pharma inc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Chlordiazepoxide: Formulary list price $0.2216/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2216 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4279 · Verify on the e-Formulary ↗ (DIN 00522996)

Source record

DIN 00522996: Chlordiazepoxide Raw flags: sec3=Y Item: 281608001; group id 483; item number 1233; lccId None; manufacturer id AAP Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.2216; ministry $0.2216 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00522996 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4279

Interchangeable products

Librium · DIN 00012645 · not recorded

Shortage status: discontinued (2026-05-11, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00522996

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Chlordiazepoxide · DIN 00522724 · 5mg · capsule

General benefitDormant since 2024-08-15 · checked 2026-09-02 · What does dormant mean?

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Chlordiazepoxide · DIN 00522724 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Dormant since 2024-08-15 · brand CHLORDIAZEPOXIDE · ATC N05BA02 CHLORDIAZEPOXIDE · form Capsule · route Oral · ingredients CHLORDIAZEPOXIDE HYDROCHLORIDE 5 MG · company Aa pharma inc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Chlordiazepoxide: Formulary list price $0.0825/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0825 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 00522724: Chlordiazepoxide Raw flags: sec3=Y Item: 281608003; group id 483; item number 1231; lccId None; manufacturer id AAP Source form: Cap; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.0825; ministry $0.0825 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00522724 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4277

Interchangeable products

Librium · DIN 00012629 · not recorded

Shortage status: active shortage (reported 2023-08-15, last updated 2024-09-11) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00522724

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2024-08-15 — choose a marketed DIN from the same-category list.

Chlordiazepoxide · DIN 00522988 · 10mg · capsule

General benefitDormant since 2024-08-18 · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Chlordiazepoxide · DIN 00522988 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Dormant since 2024-08-18 · brand CHLORDIAZEPOXIDE · ATC N05BA02 CHLORDIAZEPOXIDE · form Capsule · route Oral · ingredients CHLORDIAZEPOXIDE HYDROCHLORIDE 10 MG · company Aa pharma inc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Chlordiazepoxide: Formulary list price $0.1115/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1115 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 00522988: Chlordiazepoxide Raw flags: sec3=Y Item: 281608002; group id 483; item number 1232; lccId None; manufacturer id AAP Source form: Cap; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1115; ministry $0.1115 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00522988 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4278

Interchangeable products

Librium · DIN 00012637 · not recorded

Shortage status: discontinued (2024-06-26, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00522988

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2024-08-18 — choose a marketed DIN from the same-category list.

Librium · PIN 00012629 · 5mg · capsule

Listed, not a benefitOntario PIN; no Health Canada record under this code

StatusListed, not a benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Librium · DIN 00012629 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check this DIN again

Librium: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 00012629)

Source record

DIN 00012629: Librium Raw flags: notABenefit=Y, sec3=Y Item: 281608003; group id 483; item number 1231; lccId None; manufacturer id HLR Source form: Cap; strength: 5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00012629 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Interchangeable products

Chlordiazepoxide · DIN 00522724 · $0.0825

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00012629

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Librium · PIN 00012637 · 10mg · capsule

Listed, not a benefitOntario PIN; no Health Canada record under this code

StatusListed, not a benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Check Health Canada brand search

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Librium · DIN 00012637 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check this DIN again

Librium: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 00012637)

Source record

DIN 00012637: Librium Raw flags: notABenefit=Y, sec3=Y Item: 281608002; group id 483; item number 1232; lccId None; manufacturer id HLR Source form: Cap; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00012637 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Interchangeable products

Chlordiazepoxide · DIN 00522988 · $0.1115

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Librium · PIN 00012645 · 25mg · capsule

Listed, not a benefitOntario PIN; no Health Canada record under this code

StatusListed, not a benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Check Health Canada brand search

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Librium · DIN 00012645 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check this DIN again

Librium: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 00012645)

Source record

DIN 00012645: Librium Raw flags: notABenefit=Y, sec3=Y Item: 281608001; group id 483; item number 1233; lccId None; manufacturer id HLR Source form: Cap; strength: 25mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00012645 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Interchangeable products

Chlordiazepoxide · DIN 00522996 · $0.2216

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ALPRAZOLAM

· 12 products · General benefit (6), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 0.25mg, 0.5mg, 1mg, 2mg · Tab

BROMAZEPAM

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 1.5mg, 3mg, 6mg · Tab

CLORAZEPATE DIPOTASSIUM

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 3.75mg, 7.5mg, 15mg · Cap

DIAZEPAM

· 10 products · Limited Use, codes 481 (1), General benefit (6), Listed, not a benefit (3) · strengths: 5mg/mL, 10mg/2mL, 15mg/3mL, 2mg, 5mg, 10mg · Inj Sol (Preservative Free), Rect Gel-2x 5mg Pk, Rect Gel-2x10mg Pk, Rect Gel-2x15mg Pk, Tab

LORAZEPAM

· 12 products · General benefit (9), Listed, not a benefit (3) · strengths: 0.5mg, 1mg, 2mg · Tab

OXAZEPAM

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 10mg, 15mg, 30mg · Tab

HYDROXYZINE HCL

· 8 products · Listed, not a benefit · strengths: 10mg, 25mg, 50mg · Cap

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more

Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

1 INDICATIONS CHLORDIAZEPOXIDE (chlordiazepoxide hydrochloride) is indicated:  For the symptomatic relief of mild anxiety and tension, and for reduction of tension states that may accompany muscle spasm.  As an adjunct in tension states associated with insomnia, pre- and post- operative apprehension, tension headache, premenstrual tension and stress, and functional gastrointestinal, cardiovascular, gynecological, and dermatological disorders with an emotional overlay.  For the alleviation of alcohol withdrawal syndromes.  To reduce anxiety associated with psychosis. Chlordiazepoxide should not be used in place of appropriate treatment in psychotic patients. 1.1 Pediatrics Pediatrics (< 18 years of age): Health Canada has not authorized an indication for the pediatric population (see 4.2 Recommended Dose and Dosage Adjustment). 1.2 Geriatrics Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. See 7.1.4 Geriatrics. Long-term use of CHLORDIAZEPOXIDE should be avoided in elderly patients. En… https://pdf.hres.ca/dpd_pm/00066938.PDF PM date: December 31, 1981 Source product: CHLORDIAZEPOXIDE; DIN 00522996; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Chlordiazepoxide · DIN 00522996 Shortage status: discontinued (2026-05-11, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00522996

Check this DIN again

Chlordiazepoxide · DIN 00522724 Shortage status: active shortage (reported 2023-08-15, last updated 2024-09-11) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00522724

Check this DIN again

Chlordiazepoxide · DIN 00522988 Shortage status: discontinued (2024-06-26, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00522988

Check this DIN again

Health Canada: dormant products

Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Librium: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026